2026 Oncology Drug Development Planning Realities

Read article

Medelis Partners With Insight Genetics to Deliver Molecular Diagnostics to Oncology Sponsors and Patients

Increasing the effectiveness of cancer treatments is an…
Read Article

Things to Remember When Planning Your Phase I Oncology Study

Oncology trials are complex, especially first-in-human phase I…
Read Article

The Importance of Bid Transparency in a CRO Proposal

Planning an oncology study requires a tremendous amount…
Read Article

The PD-1 Era Is Officially Here

On July 4th Ono Pharmaceuticals announced that it…
Read Article

Medelis Adds Marketing MO Co-founder Jim Sagar to Board of Directors

Medelis, Inc. today announced that Jim Sagar, CEO of…
Read Article

In Memory of Robert T. Bosserman

Medelis Inc. is deeply saddened to announce the…
Read Article

FDA Breakthrough Therapy Designation: A Pathway for Expedited Drug Development

On July 9, 2012 the Food and Drug…
Read Article

New FDA Guidance – A Risk-Based Approach to Monitoring Clinical Trials

As clinical trials have become increasingly complex, clinical…
Read Article

Adaptive Trial Design in Clinical Trials Growing in Popularity

A recent industry and regulatory discussion has revealed…
Read Article